Over the past decade surgical site infections (SSIs) have been recognized as a preventable and costly complication-costly not only in a monetary sense, but also in regard to both morbidity and mortality. Estimates for annual expenditures to manage SSIs in the US range from $3.5 to $10 billion, not surprising when the average 30-day cost of a single organ/space SSI after hysterectomy approaches $20,000.1-3 Notably, these figures do not account for lost wages and long-term disability. Additionally, deaths among patients who develop a SSI are directly attributable to the infection in 77 % of cases, and for patients with ovarian cancer, diagnosis of a SSI increases the risk of death by 50 %.